Holen Sie sich die Stockscreener-App
55.05
0.07%
0.04
Handel nachbörslich:
54.60
-0.45
-0.82%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 10,000 Shares - MarketBeat
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock By Investing.com - Investing.com UK
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock - Investing.com South Africa
Arrowhead Pharmaceuticals CMO Sells 10,000 Shares - TradingView
Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc. - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8%What's Next? - MarketBeat
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - MarketBeat
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (ARWR) Competitors - Meyka
ARWR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners - simplywall.st
Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co. - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR) - simplywall.st
Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Net current asset value per share of Arrowhead Pharmaceuticals, Inc. – DUS:HDP1 - TradingView
Arrowhead Pharmaceuticals Achieves 201.24% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (ARWR): An Investor Outlook on Its 28.86% Potential Upside - DirectorsTalk Interviews
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
Responsive Playbooks and the ARWR Inflection - Stock Traders Daily
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp - MarketBeat
Reviewing Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Nutra Pharma (OTCMKTS:NPHC) - Defense World
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity - ChartMill
Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - Defense World
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited - Finviz
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited - Yahoo Finance
Strategic Shift in Biopharma Dealmaking - Intellectia AI
Fundamentals Check: Can Arrowhead Pharmaceuticals Inc weather a recessionEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential - DirectorsTalk Interviews
Piper Sandler highlights Arrowhead Pharmaceuticals, Inc. (ARWR) pipeline with upcoming phase III hypertriglyceridemia data - MSN
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock benefit from automationJuly 2025 Review & Weekly Chart Analysis and Trade Guides - mfd.ru
What’s the beta of Arrowhead Pharmaceuticals Inc. stockWeekly Trade Recap & Accurate Entry and Exit Point Alerts - mfd.ru
What are Arrowhead Pharmaceuticals Inc.’s recent SEC filings showingProfit Target & Capital Protection Trading Alerts - mfd.ru
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Is Arrowhead Pharmaceuticals Inc. gaining market shareTrade Risk Assessment & Verified Momentum Stock Watchlist - mfd.ru
Zacks Research Issues Negative Estimate for ARWR Earnings - MarketBeat
Johnson Investment Counsel Inc. Makes New $781,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):